Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.15 AUD | +15.31% | +17.32% | +80.06% |
May. 31 | Telix Pharma Reports Positive Data from Clinical Study of Prostate Cancer Drug; Shares Surge 15% | MT |
May. 31 | Commodity, banking stocks help Australian shares snap 3-day slide | RE |
Sales 2024 * | 744M 495M | Sales 2025 * | 940M 625M | Capitalization | 6.13B 4.08B |
---|---|---|---|---|---|
Net income 2024 * | 54M 35.92M | Net income 2025 * | 104M 69.18M | EV / Sales 2024 * | 8.1 x |
Net cash position 2024 * | 105M 69.89M | Net cash position 2025 * | 199M 132M | EV / Sales 2025 * | 6.31 x |
P/E ratio 2024 * |
109
x | P/E ratio 2025 * |
56.9
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.38% |
Latest transcript on Telix Pharmaceuticals Limited
1 day | +15.31% | ||
1 week | +17.32% | ||
1 month | +23.72% | ||
3 months | +52.14% | ||
6 months | +83.15% | ||
Current year | +80.06% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
Founder | 49 | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
Founder | 49 | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | 64 | 17-09-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 14 M€ | -5.07% | ||
0.04% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 18.15 | +15.31% | 3,572,958 |
24-05-30 | 15.74 | +0.77% | 898,935 |
24-05-29 | 15.62 | +0.97% | 778,826 |
24-05-28 | 15.47 | -2.64% | 725,007 |
24-05-27 | 15.89 | +2.71% | 1,016,542 |
Delayed Quote Australian S.E., May 31, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+80.06% | 4.07B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- TLX Stock